{
    "clinical_study": {
        "@rank": "73834", 
        "arm_group": [
            {
                "arm_group_label": "Trivalent influenza virus vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H3N2 (A/Texas/50/2012), B (B/Massachusetts/2/2012) and B (B/Brisbane/60/2008)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.5 mL of sucrose-phosphate buffer"
            }
        ], 
        "brief_summary": {
            "textblock": "This prospective annual release study is designed to evaluate the safety on new influenza\n      virus vaccine strains to be included in FluMist Quadrivalent for the 2013-2014 influenza\n      season."
        }, 
        "brief_title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "This prospective, randomized, double-blind, placebo-controlled release study will enroll\n      approximately 300 healthy adults 18 to 49 years of age. Eligible subjects will be randomly\n      assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by\n      intranasal spray. Randomization will be stratified by site. This study will be conducted at\n      3 sites in the United States of America. Each subject will receive one dose of\n      investigational product on Study Day 1. The duration of study participation for each subject\n      is the time from study vaccination through 180 days after study vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18 through 49 years\n\n          2. Written informed consent\n\n          3. Subject available by telephone\n\n          4. Ability to understand and comply with the requirements of the protocol, as judged by\n             the investigator\n\n        Exclusion Criteria:\n\n          1. Concurrent enrollment in another clinical study up to 180 days after receipt of\n             investigational product (Day 181)\n\n          2. History of hypersensitivity to any component of the vaccine, including egg or egg\n             protein or serious, life threatening, or severe reactions to previous influenza\n             vaccinations\n\n          3. Any condition for which the inactivated influenza vaccine is indicated, including\n             chronic disorders of the pulmonary or cardiovascular systems (eg, asthma), chronic\n             metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies\n             that required regular medical follow-up or hospitalization during the preceding year\n\n          4. Acute febrile (> 100.0\u00b0F oral or equivalent) and/or clinically significant\n             respiratory illness (eg, cough or sore throat) within 14 days prior to randomization\n\n          5. Any known immunosuppressive condition or immune deficiency disease, including human\n             immunodeficiency virus infection, or ongoing immunosuppressive therapy\n\n          6. History of Guillain-Barr\u00e9 syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859143", 
            "org_study_id": "MED-VA-FLUMIST-1156"
        }, 
        "intervention": [
            {
                "arm_group_label": "Trivalent influenza virus vaccine", 
                "description": "Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H3N2(A/Texas/50/2012), B (B/Massachusetts/2/2012) and B (B/Brisbane/60/2008)", 
                "intervention_name": "Trivalent influenza vaccine virus", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo is supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Trivalent, Influenza, FluMist, Vaccine, Prevention", 
        "lastchanged_date": "January 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockbridge", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "92739"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults", 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Raburn Mallory, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Fever is defined as oral temperature greater than or equal to 101 degrees Fahrenheit.", 
            "measure": "Number of Subjects Reporting Fever", 
            "safety_issue": "Yes", 
            "time_frame": "Study Days 1 - 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859143"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Subjects Reporting Other Solicited Symptoms Post Treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1- 8"
            }, 
            {
                "measure": "Number of Subjects Reporting Any Adverse Event (AE) Post Treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1- 8"
            }, 
            {
                "measure": "Number of Subjects Reporting Other Solicited Symptoms Post Treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1 - 15"
            }, 
            {
                "measure": "Number of Subjects Reporting Any Adverse Event (AEs) Post Treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1 - 15"
            }, 
            {
                "measure": "Number of Subjects Reporting Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1 - 29"
            }, 
            {
                "measure": "Number of Subjects Reporting Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1 - 181"
            }, 
            {
                "measure": "Number of Subjects Reporting New Onset Chronic Diseases (NOCDs)", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1 - 29"
            }, 
            {
                "measure": "Number of Subjects Reporting New Onset Chronic Diseases (NOCDs)", 
                "safety_issue": "Yes", 
                "time_frame": "Study Days 1 - 181"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}